16 October 2014Americas

US Supreme Court split on Teva case

The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

US Supreme Court hears Teva arguments in Copaxone case

15 October 2014 The highest court in the US will hear a dispute today (October 15) between pharmaceutical company Teva and generic rivals that are looking to market versions of its multiple sclerosis drug Copaxone (glatiramer acetate).

Teva asks US Supreme Court to stay ruling in Copaxone case

8 April 2014 Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

More on this story

US Supreme Court hears Teva arguments in Copaxone case

15 October 2014 The highest court in the US will hear a dispute today (October 15) between pharmaceutical company Teva and generic rivals that are looking to market versions of its multiple sclerosis drug Copaxone (glatiramer acetate).

Teva asks US Supreme Court to stay ruling in Copaxone case

8 April 2014 Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

More on this story

US Supreme Court hears Teva arguments in Copaxone case

15 October 2014 The highest court in the US will hear a dispute today (October 15) between pharmaceutical company Teva and generic rivals that are looking to market versions of its multiple sclerosis drug Copaxone (glatiramer acetate).

Teva asks US Supreme Court to stay ruling in Copaxone case

8 April 2014 Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids

Kilpatrick adds ‘seasoned litigator’ as trademark partner

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

Startup challenges rival over brain monitoring tech at ITC